Iris metastasis from prostate carcinoma: A case report and review of the literature

Martin, V.; Cuenca, X.; López, S Javier; Albertini, Anne Flore; Lang, Patricia; Simon, J.-M.; Hemery, C.; Feuvret, L.; Mazeron, J. J.

doi:10.1016/j.canrad.2014.12.008

Cited by 12 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detailed treatment course was obtained for eight cases [11][12][13][14][15][16][17][18] in which the brain metastases were sensitive to hormonal therapy. Moreover, 23 cases (18 reports) [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] of intracranial metastasis of CRPC were identified. To clarify the characteristics of intracranial metastases of CPRC, these 23 cases are reviewed in Table 1.…”

Section: Brain Metastases Of Prostate Cancermentioning

confidence: 99%

Headache Caused by Brain Metastases of Castration-resistant Prostate Cancer during Cabazitaxel Therapy

et al. 2017

View full text Add to dashboard Cite

We describe the case of a 55-year-old man who underwent four cycles of cabazitaxel therapy for castration-resistant prostate cancer (CRPC). After the fourth cycle of cabazitaxel, the patient experienced severe headaches. Brain gadolinium (Gd) contrast-enhanced magnetic resonance imaging (MRI) revealed multiple brain metastases. A few days later, the patient suffered impaired consciousness that progressed rapidly. The patient was treated for the symptoms of increased intracranial pressure and underwent whole-brain radiation. One month later, the patient's consciousness level and headache had improved. Although brain metastases of prostate cancer are rare, the possibility of brain metastases should be considered for prostate cancer patients, especially when a CRPC patient complains of headache. Additionally, even if major conditions such as cerebral hemorrhage are excluded by the use of non-contrastenhanced computed tomography, brain Gd contrast-enhanced MRI should be performed in consideration of the possibility of brain metastases of prostate cancer.

show abstract

Section: Brain Metastases Of Prostate Cancermentioning

confidence: 99%

Headache Caused by Brain Metastases of Castration-resistant Prostate Cancer during Cabazitaxel Therapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Serum prostate-specific antigen (PSA) is a reliable clinical marker to monitor prostatic diseases including not only prostate cancer but also prostatic hyperplasia and inflammation. In the field of ophthalmology, prostate cancer also makes iris metastases, 6 as part of the uvea, and orbital metastases. 7 In this study, we report a patient who presented with a choroidal tumor as the initial sign.…”

Section: Introductionmentioning

confidence: 99%

Prostate Cancer Detected by Choroidal Tumor and Complete Response to Hormonal Therapy: Case Report and Literature Review of 24 Patients With Choroidal Metastasis From Prostate Cancer

Matsuo¹,

Tanaka

Nakamura

et al. 2021

Journal of Investigative Medicine High Impact Case Reports

View full text Add to dashboard Cite

Metastatic choroidal tumors derived from prostate cancer are rare. In this study, we report a patient who manifested a choroidal tumor as the initial presenting sign of prostate cancer and review 23 patients with choroidal metastasis of prostate cancer in the literature to answer a clinical question how the choroidal metastases would respond to hormonal therapy. A 73-year-old man presented with a choroidal tumor in the right eye. He was in good health and had no previous history except for current hemodialysis in 3 years due to chronic renal failure as a sequel to glomerulonephritis. With the diagnosis of a probable metastatic tumor, positron emission tomography was performed to disclose high-uptake sites in multiple bones, lymph nodes, and the prostate, together with multiple nodular lesions in bilateral lungs on computed tomography (CT) scan. Serum prostate-specific antigen (PSA) was elevated to 541 ng/mL, which supported prostate cancer as the primary site. He had degarelix injection, and the choroidal tumor resolved rapidly and became flat degeneration in a month. Prostate biopsy showed poorly differentiated adenocarcinoma, and he underwent surgical castration. He had no medication until 3 years later when he showed gradual increase of serum PSA up to 6.05 ng/mL and multiple bony metastases on CT scan. Bicalutamide, switched to enzalutamide and then to abiraterone, led to the undetectable level of serum PSA until the last visit with no relapse of the choroidal metastasis, 6.8 years after the initial visit. In the literature review of 24 patients with choroidal metastasis of prostate cancer, including this patient, 8 patients presented a choroidal tumor as the initial sign and the choroidal lesions mostly showed complete response to hormonal therapy. Among 13 patients who were frequently in the course of hormonal therapy, choroidal metastases showed complete or partial response to external beam radiation to the eye in 11 patients and episcleral plaque radiotherapy in 2 patients. In conclusion, metastatic choroidal tumors of prostate cancer would show good response to hormonal therapy when the therapy has not been initiated. Hormone-resistant choroidal metastases in the therapeutic course of prostate cancer could be managed successfully by external beam radiation to the eye.

show abstract

Uveal Metastatic Tumors

Bornfeld¹,

Singh²

2019

Clinical Ophthalmic Oncology

View full text Add to dashboard Cite

Iris metastasis from prostate carcinoma: A case report and review of the literature

Cited by 12 publications

References 11 publications

Headache Caused by Brain Metastases of Castration-resistant Prostate Cancer during Cabazitaxel Therapy

Headache Caused by Brain Metastases of Castration-resistant Prostate Cancer during Cabazitaxel Therapy

Prostate Cancer Detected by Choroidal Tumor and Complete Response to Hormonal Therapy: Case Report and Literature Review of 24 Patients With Choroidal Metastasis From Prostate Cancer

Uveal Metastatic Tumors

Contact Info

Product

Resources

About